Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation.
暂无分享,去创建一个
Hai-Quan Mao | John W Hickey | Jonathan P Schneck | H. Mao | Gregory P Howard | J. Schneck | Fernando P Vicente | J. Hickey
[1] J. Edwards,et al. Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.
[2] J. Schneck,et al. Linking form to function: Biophysical aspects of artificial antigen presenting cell design. , 2015, Biochimica et biophysica acta.
[3] A. Lanzavecchia,et al. From TCR Engagement to T Cell Activation A Kinetic View of T Cell Behavior , 1999, Cell.
[4] M. Jenkins,et al. The Role of Naive T Cell Precursor Frequency and Recruitment in Dictating Immune Response Magnitude , 2012, The Journal of Immunology.
[5] Yuval Dor,et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. , 2005, Genes & development.
[6] Ronnie H. Fang,et al. Nanoparticle-Based Modulation of the Immune System. , 2016, Annual review of chemical and biomolecular engineering.
[7] A. Mackensen,et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells , 2003, Nature Medicine.
[8] G. Nolan,et al. Duration of antigen receptor signaling determines T-cell tolerance or activation , 2010, Proceedings of the National Academy of Sciences.
[9] Cheng Zhu,et al. Insights from in situ analysis of TCR–pMHC recognition: response of an interaction network , 2013, Immunological reviews.
[10] S. Rosenberg,et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.
[11] J. Yewdell,et al. Endogenous viral antigen processing generates peptide-specific MHC class I cell-surface clusters , 2012, Proceedings of the National Academy of Sciences.
[12] Sai T Reddy,et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.
[13] H. Eisen,et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. , 1996, Immunity.
[14] S. Ugel,et al. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. , 2009, Cancer research.
[15] Levi A. Gheber,et al. Domains in cell plasma membranes investigated by near-field scanning optical microscopy. , 1998, Biophysical journal.
[16] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[17] Tarek R. Fadel,et al. Enhanced cellular activation with single walled carbon nanotube bundles presenting antibody stimuli. , 2008, Nano letters.
[18] A. Scheffold,et al. Fine Tuning and Efficient T Cell Activation with Stimulatory aCD3 Nanoarrays , 2013, Nano letters.
[19] Robert L. Tanguay,et al. Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices. , 2017, Nature nanotechnology.
[20] Thomas M. Schmitt,et al. Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients , 2013, Science Translational Medicine.
[21] Jonathan P Schneck,et al. Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. , 2014, Biomaterials.
[22] Cheng Zhu,et al. The kinetics of two dimensional TCR and pMHC interactions determine T cell responsiveness , 2010, Nature.
[23] J. Sunshine,et al. Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. , 2015, Small.
[24] M. Edidin,et al. Magnetic Field-Induced T Cell Receptor Clustering by Nanoparticles Enhances T Cell Activation and Stimulates Antitumor Activity , 2014, ACS nano.
[25] Ronald D. Vale,et al. A DNA-Based T Cell Receptor Reveals a Role for Receptor Clustering in Ligand Discrimination , 2016, Cell.
[26] Weiguo Lu,et al. Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma , 2010, Journal of experimental & clinical cancer research : CR.
[27] Mark M Davis,et al. TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation , 2010, Nature Immunology.
[28] B. Alarcón,et al. Cognate Peptide–MHC Complexes Are Expressed as Tightly Apposed Nanoclusters in Virus-Infected Cells To Allow TCR Crosslinking , 2014, The Journal of Immunology.
[29] Mark M. Davis,et al. Determination of the Relationship Between T Cell Responsiveness and the Number of MHC-Peptide Complexes Using Specific Monoclonal Antibodies1 , 2000, The Journal of Immunology.
[30] J. Green,et al. Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. , 2017, Biomaterials.
[31] M. Luscher,et al. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis , 1991, Nature.
[32] Warren C W Chan,et al. Mediating tumor targeting efficiency of nanoparticles through design. , 2009, Nano letters.
[33] Daniel Coombs,et al. Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide MHC Confinement Time , 2010, Immunity.
[34] R C Brower,et al. Minimal requirements for peptide mediated activation of CD8+ CTL. , 1994, Molecular immunology.
[35] Penelope A. Morel,et al. Dominant Role of Antigen Dose in CD4+Foxp3+ Regulatory T Cell Induction and Expansion1 , 2009, The Journal of Immunology.
[36] H. Grey,et al. The minimal number of class II MHC-antigen complexes needed for T cell activation. , 1990, Science.
[37] Tarek R. Fadel,et al. A carbon nanotube-polymer composite for T-cell therapy. , 2014, Nature nanotechnology.
[38] Michael Loran Dustin,et al. T Cell Activation is Determined by the Number of Presented Antigens , 2013, Nano letters.
[39] S. K. Watkins,et al. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells , 2012, Cancer Immunology, Immunotherapy.
[40] Tarek R. Fadel,et al. An Artificial Antigen-presenting Cell with Paracrine Delivery of IL-2 Impacts the Magnitude and Direction of the T Cell Response* , 2011, The Journal of Biological Chemistry.
[41] K. Kinzler,et al. Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. , 2015, ACS nano.
[42] A. Riva,et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer , 2003, British Journal of Cancer.
[43] P. Roche,et al. Major Histocompatibility Complex (MHC) Class II-Peptide Complexes Arrive at the Plasma Membrane in Cholesterol-rich Microclusters* , 2013, The Journal of Biological Chemistry.
[44] O. Eremin,et al. Dendritic cells are dysfunctional in patients with operable breast cancer , 2004, Cancer Immunology, Immunotherapy.
[45] Evan W. Newell,et al. TCR–peptide–MHC interactions in situ show accelerated kinetics and increased affinity , 2010, Nature.
[46] F. Marincola,et al. Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.
[47] Gigi Kwik Grönvall,et al. Clustering Class I MHC Modulates Sensitivity of T Cell Recognition1 , 2006, The Journal of Immunology.
[48] Emil R. Unanue,et al. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation , 1990, Nature.
[49] Michael Loran Dustin,et al. T Cell Receptor Signaling Precedes Immunological Synapse Formation , 2002, Science.
[50] P. Lenne,et al. Molecular clustering in the cell: from weak interactions to optimized functional architectures. , 2016, Current opinion in cell biology.
[51] J. L. Santos,et al. Control of polymeric nanoparticle size to improve therapeutic delivery. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[52] H. Grey,et al. The minimal number of antigen‐major histocompatibility complex class II complexes required for activation of naive and primed T cells , 1997, European journal of immunology.
[53] Mark M Davis,et al. T cell killing does not require the formation of a stable mature immunological synapse , 2004, Nature Immunology.
[54] A. Mackensen,et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Greg M. Delgoffe,et al. Anergic T Cells Are Metabolically Anergic1 , 2009, The Journal of Immunology.
[56] D. Bray,et al. Receptor clustering as a cellular mechanism to control sensitivity , 1998, Nature.
[57] Steven A. Rosenberg,et al. Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.
[58] P. Schwille,et al. Cholesterol and Sphingomyelin Drive Ligand-independent T-cell Antigen Receptor Nanoclustering* , 2012, The Journal of Biological Chemistry.
[59] Michael Loran Dustin,et al. Nanoscale ligand spacing influences receptor triggering in T cells and NK cells. , 2013, Nano letters.
[60] M. Jackson,et al. High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility complex class I proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[61] Pau Serra,et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. , 2010, Immunity.
[62] M. Edidin,et al. Nanoscale artificial antigen presenting cells for T cell immunotherapy. , 2014, Nanomedicine : nanotechnology, biology, and medicine.